What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

about

Colorectal cancer: epigenetic alterations and their clinical implications.

P2860

Q46112381-8AA31510-7523-4574-A5DB-3F4919231D81

P2860

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

Item

http://www.wikidata.org/entity/Q39306576

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@en

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@nl

type

Item

label

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@en

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@nl

prefLabel

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@en

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@nl

P1476

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

@en

P2093

Alberto Puccini

http://www.w3.org/2001/XMLSchema#string

Martin D Berger

http://www.w3.org/2001/XMLSchema#string

Wu Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer classification using the Immunoscore: a worldwide task force

Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

The three Es of cancer immunoediting

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont

P2888

s11523-017-0494-5

P304

265-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0494-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Heinz-Josef Lenz

P577

2017-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28504299

http://www.w3.org/2001/XMLSchema#string

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

about

P2860

P2860

What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698